Siltuximab Completed Phase 2 Trials for Multiple Myeloma (MM) Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00401843A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma
NCT00402181An Efficacy and Safety Study of Siltuximab in Participants With Relapsed or Refractory Multiple Myeloma
NCT00911859A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients